Elicit Launches BioDecisionBench to Evaluate LLM Reasoning in Pharma Decisions
xuanalogue · x · 2026-08-06
Elicit's evals team has introduced BioDecisionBench, a new benchmark designed to evaluate LLMs on reasoning failures specifically in high-stakes pharmaceutical decisions. The benchmark tests models on rigorous reasoning across preclinical study design, observational study design, and the broader drug development process.
In their evaluations, Elicit's Smartest mode highlighted more key considerations for decisions, achieving a coverage of 76.7%, outperforming Claude Opus 5 Max which scored 68.8%.
More from Research
- Cryptographer Analyzes Anthropic's AI Cryptanalysis Results Beyond the Hype — JeremyCMorgan · 2026-08-06
- Benchmark Flaw: BigFinanceBench's Reference Answers Contain Serious Errors — rohanpaul_ai · 2026-08-06
- Blog: ELR Controls Weight Direction Changes, Offering a Better Tuning Alternative to Learning Rate — YouJiacheng · 2026-08-06
- AI Agents Reproduced 2,000 ICML Papers, Falsifying Over One-Third — Hugging Face · 2026-08-06
- Scholar Proposes Lowering Credibility Weights for Low-Engagement NeurIPS Reviewers — 3scorciav · 2026-08-06
- Senior PAMI-TC Ombud David Forsyth Calls for Ending Rebuttals at CVPR — 3scorciav · 2026-08-06